Psychedelics Today, Author at PsyNews.com

Home Authors Posts by Watertime

404 POSTS 0 COMMENTS

How Psychedelics Impact the Mind: Mysticism, Mental Health, and the Future...

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant...

2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

The Psychedelic News Feed: September 2, 2024 – December 29, 2024

Psychedelic Drug Development Pipeline Updates (Q1’25)

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart

How Do You Find the Right Facilitator? The Art of Matchmaking...

atai Life Sciences to Host Conference Call and Webcast to Discuss...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

1...293031...41 Page 30 of 41

EDITOR PICKS

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime

How Psychedelics Impact the Mind: Mysticism, Mental Health, and the Future...

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant...

2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

The Psychedelic News Feed: September 2, 2024 – December 29, 2024

Psychedelic Drug Development Pipeline Updates (Q1’25)

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart

How Do You Find the Right Facilitator? The Art of Matchmaking...

atai Life Sciences to Host Conference Call and Webcast to Discuss...

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

EDITOR PICKS

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY